XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$28.19 USD
-1.66 (-5.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $28.49 +0.30 (1.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
XOMA Royalty Corporation [XOMA]
Reports for Purchase
Showing records 261 - 280 ( 332 total )
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - April and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
We assume coverage with a $5 price target and a Buy rating,
Provider: Roth Capital Partners, Inc.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
We Believe Gevokizumab Demonstrated Initial Clinical Activity In Severe Inflammatory Acne
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of December 16
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of December 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Partner Servier Initiates POC Trial Testing Gevokizumab in Acute Coronary Syndrome Which Could Provide Significant Value to Xoma With Little Risk
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Partner Servier Starts Gevokizumab Study in CV Indication, as Expected
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Xmas Come Early; PATH Phase III Study in Hypertension Successful
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
With The Recent Pullback and Cash Runway Through Multiple Transforming Catalysts, We Believe It Is Time To Invest In; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
3Q12 Results; Focus on Gevo Late Stage Studies, Target Reduced to $5
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q3 Preview: We Anticipate A Pipeline Update Could Be Material.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Adds Third Study to Broad Gevokizumab Phase III Program; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J